Navigation Links
Final 12 Month Clinical Data from 5,000 Patients in Worldwide e-HEALING Clinical Study Show Good Safety and Efficacy with Real World Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM)
Date:9/22/2009

s showed a low TLR rate of 4.6 percent, a per protocol SAT and late thrombosis rate of 0.9 percent, and a MACE rate of 8.9 percent.

"The MACE rate is only 1.2 percent higher than the full cohort of the study and was mainly driven by mortality," said de Winter. "We expect a higher mortality rate in diabetic patients due to other comorbidities."

e-HEALING is a multi-center, worldwide (outside the United States) prospective clinical study conducted in 31 countries at 144 clinical centers. In addition to 25 percent of patients having diabetes mellitus, 42.4 percent of the patients had unstable angina and 11 percent had pre-procedure thrombus. For the lesions treated, 49.3 percent were type B2 or C. The study protocol recommends that patients receive one month of clopidogrel treatment after the index procedure. The primary endpoint of the study is target vessel failure at 12 months. The advanced electronic data capture via the internet with built in consistency checks for data monitoring was conducted by KIKA Clinical Solutions, a leading provider of advanced EDC solutions for clinical trials. Cardialysis, an independent Contract Research Organization (CRO), ensured quality, consistency and completeness of the data through comprehensive data management and monitoring.

Sigmund Silber, M.D., F.A.C.C., F.E.S.C., a professor of medicine with the Cardiology Practice and Hospital, Munich, and co-principle investigator, said, "Physicians rely on evidence-based recommendations for coronary interventions, and results from multicenter studies are more meaningful than those from a single center. The results from the large, multicenter e-HEALING study demonstrate the safety and efficacy of the Genous Bio-engineered R stent in a broad patient population - including remarkable outcomes for diabetic patients. This patient population shows a similar clinical outcome at 12-month follow-up compared to the total e-HEALING cohort,
'/>"/>

SOURCE OrbusNeich
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Cadient Group Selected as Finalist in Medical Marketing & Media Awards
2. Prix Galien USA Announces 2009 Final Candidates
3. Quest Diagnostics Announces Final Tender Offer Results
4. Valeant Pharmaceuticals Reports Encouraging Final Results With Taribavirin Phase IIb Study
5. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
6. Encorium Named as Finalist for the Second Annual Vaccine Industry Excellence Award
7. Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer
8. Quest Diagnostics Finalizes Previously Announced Settlement With Government Related to Test Kit Subsidiary Closed in 2006
9. Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Researchs 100th Annual Meeting
10. University of Maryland Announces Finalists for $75K Business Plan Competition
11. Impact Systems' Compliance-in-a-Box™ Video is Announced as "Be the Buzz of Bio" Contest Finalist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... Based on the revenues gained from surgical ... dominated by four major players contributing to approximately ... include GE Healthcare (U.K.), Siemens AG (Germany), Philips ... Report Copy at http://www.marketsandmarkets.com/Market-Reports/surgical-imaging-market-210534462.html , The ... to its strong product portfolio, which includes its ...
(Date:12/17/2014)... Beach, CA (PRWEB) December 17, 2014 ... Inc. to provide a larger packaged waste water treatment ... in King Abdullah Economic City (KAEC). Two years ago ... EMAAR’s Jeddah Gate Development, serving two residential towers with ... capacity is over a quarter million gallons per day ...
(Date:12/17/2014)... Diego, CA (PRWEB) December 17, 2014 ... and activation agency and member of the Huntsworth Health ... Gonzales to its executive team. In her role, Gonzales ... , “We are incredibly honored to welcome a ... Agency Chief and CEO, Gaëtan Fraikin. “She is a ...
(Date:12/17/2014)... Dec. 17, 2014 Tigercat Pharma, Inc. ... study evaluating the investigational oral NK-1 receptor antagonist ... severe, chronic itch who are unresponsive or inadequately ... topical steroids and antihistamines. The ... Analog Scale (VAS) itch score from baseline, comparing ...
Breaking Biology Technology:Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 2Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 3Global Refurbished Surgical Imaging Market by Product & Application is Estimated to Reach $1.25 Billion by 2019 - New Research Report by MarketsandMarkets 4Audacity Welcomes Healthcare Communications Expert Jamie Gonzales as Senior Vice President of Client Services 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4
... Draws Participants From A Broad Range of Industries Despite ... edition of InformexUSA officially opened its exhibition floors Wednesday ... show traffic in 2008. The week long exhibition & ... in North America, is featuring an expanded program to ...
... Mass., Jan. 29 Repligen Corporation (Nasdaq: ... Chief Executive Officer, Walter C. Herlihy, Ph.D., will host ... 2009 at 10:00 a.m. EST, to report third quarter ... quarterly update of the Company.This call is being webcast ...
... 29, 2009 Senomyx, Inc. (Nasdaq: SNMX ) ... fiscal year ending December 31, 2008 on Thursday, February 12, ... The Company will also host a conference call and live ... Time) that same day. During the call, Senomyx,s management ...
Cached Biology Technology:InformexUSA 2009 Opens to Strong Attendance 2InformexUSA 2009 Opens to Strong Attendance 3InformexUSA 2009 Opens to Strong Attendance 4Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 2Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results 3SENOMYX, INC. fourth quarter AND FISCAL YEAR-END 2008 Earnings conference call scheduled for February 12, 2009 2
(Date:11/18/2014)... -- The Secure Identity & Biometrics Association (SIBA) and ... formation of The Airport Entry and Exit Working ... Biometric Entry and Exit Solutions Framework for Airports ... BORDERPOL, the international non-profit organization that works directly ... border security, traveler and migration systems. ...
(Date:11/15/2014)... YORK , Nov. 13, 2014  While we may ... technology Doctor McCoy used in "Star Trek" to gain instant ... tools designed to work with smartphones and tablets for monitoring ... of the healthcare world. This may seem a tad Orwellian ... ready to adopt some of these technological opportunities into their ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 2Identity Management, Document Authentication and Biometric Companies Form "The Airport Entry and Exit Working Group", Releasing the Framework to Help Guide the Department of Homeland Security and Congress Towards Solutions 3Americans May Be Ready for a Brave New World of Healthcare 2Americans May Be Ready for a Brave New World of Healthcare 3Americans May Be Ready for a Brave New World of Healthcare 4
... rich in omega-3 fatty acids can inhibit growth of breast ... from the University of Guelph. The study, published recently ... to be the first to provide unequivocal evidence that omega-3s ... Ma, a professor in Guelph,s Department of Human Health and ...
... Washington, DC The Entomological Society of America (ESA) ... today a new partnership that will provide ESA members ... policy debates. The ESA is the ... scientific needs of entomologists and individuals in related disciplines. ...
... of Southampton have identified the molecular system that ... brain during neurodegenerative diseases. An important aspect ... Huntington,s or prion disease, is the generation of ... Results from the study open new avenues ...
Cached Biology News:Omega-3s inhibit breast cancer tumor growth, study finds 2Entomological Society of America launches science policy program 2Scientists identify molecular system that could help develop treatments for Alzheimer's disease 2
Recorder, 6", 7 Day, 1 Pen, 0 to 100°C, 220V, 50/60 Hz, for 4520, Customer Installed...
... Serotec STAR3000 HISTAR detection systems ... to be used with species specific ... in tissue specimens. Visualisation is accomplished ... that utilises novel polymer labelling technology. ...
Taq DNA Polymerase (T. aquaticus), 250 units. For PCR and other procedures requiring DNA polymerase activity at elevated temperatures. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzyme...
... Polymerase is the most thoroughly characterized enzyme ... to its overall utility and efficacy. , ... for PCR applications. , It is ... ,, AmpliTaq DNA Polymerase is a 94 ...
Biology Products: